Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
 Index 
 Full text 
Verbatim report of proceedings
Thursday, 3 April 2014 - Brussels Revised edition

Clinical trials on medicinal products for human use (A7-0208/2013 - Glenis Willmott)
MPphoto
 
 

  Raül Romeva i Rueda (Verts/ALE), in writing. - In favour. We concentrated our work on transparency and the role of the Ethics Committee. There was a huge campaign from civil society for transparency of clinical trial data. On the other hand, the pharmaceutical industry wanted to subject such data to their very far-ranging understanding of what would be commercially confidential. We not only called strongly for the clinical study report to be uploaded into the EU database, but were also the driving force behind ensuring also that the law explicitly specifies that clinical study reports should not be considered commercially confidential. This would not have happened without us, this is a clear victory for us. We were also keen to re-introduce an Ethics Committee, and requiring a positive opinion by them to allow a trial to go ahead.

 
Legal notice - Privacy policy